provides a classification of low-grade tumors of the central nervous system. The most common low-grade glioma is the ordinary astrocytoma. Once divided into fibrillary and protoplasmic subtypes, this lesion currently is thought to be derived from ordinary astrocytes, and it usually occurs as a relatively homogeneous but infiltrative lesion. Closely related is the mixed glioma (mixed oligoastrocytoma) that consists of both astrocytoma cells and oligodendroglioma phenotypes in varying proportions. The subcategory "low-grade" tends to exclude those lesions with features of a high degree of pleomorphism, necrosis, or vascular proliferation, or large numbers of mitoses. The pilocytic (juvenile) astrocytoma is a characteristic, more circumscribed lesion occurring primarily in childhood and with a predilection for being located in the cerebellum. It usually appears as a cystic tumor with a mural nodule. The tumor tissue itself may have features of microcystic degeneration and Rosenthal fibers which are degenerative structures in the astrocytic processes. Other reasonably common types of low-grade gliomas include the low-grade oligodendroglioma and the low-grade ependymoma, which is usually anatomically related to the ventricular ependymal lining.
There is a large variety of uncommon tumors also categorized as low-grade gliomas. The optic nerve glioma is very frequently found in the context of NF Type 1. It can occur as an "anterior" lesion that affects one or both optic nerves, primarily evolving in the optic nerve sheath, or a "posterior" lesion that involves the optic chiasm and occasionally the hypothalamus. In approximately 40% of patients harboring these lesions evidence of NF Type 1 is observed. 2 Another genetically related low-grade glioma is the subependymal giant cell astrocytoma associated with tuberous sclerosis. The characteristic location as well as its association with giant cells help define this lesion. There are some indolent tumors categorized as low-grade gliomas that commonly present with seizures. They include two mixed neuronal-glial tumors: the ganglioglioma, which may also be cystic and partially calcified, and the dysembryoplastic neuroepithelial tumor, which is usually located in the temporal lobe. The pleomorphic xanthoastrocytoma is a characteristic superficial tumor also associated with seizures. These lesions ordinarily have quite a low proliferative activity and often can be controlled by treatment with radical but subtotal resection alone.
The central neurocytoma is a peculiar and uncommon tumor, likely of neuronal derivation. These tumors are frequently associated with the third ventricle and also have an indolent course.
Some investigators classify choroid plexus papillomas together with the gliomas. These tumors arise from the choroid plexus, either in the lateral ventricles, the third ventricle, or the fourth ventricle, and frequently present as obstructive masses.
CLINICAL FEATURES OF LOW-GRADE GLIOMAS
It is clear that the location of the lesion tends to be the most important factor in determining the nature of the symptoms and signs. Because these lesions are usually slow growing, seizures may be the presenting clinical symptom and may precede the diagnosis by many years. Seizures are particularly likely to occur in cases in which the lesions involve the temporal and the frontal lobes.
Visual symptoms are relatively common in low-grade gliomas, depending on the actual location of the tumor, and its involvement of the optic apparatus or optic pathways.
In cases of slowly progressive lesions that expand to affect important areas of the brain, the patients may present with progressive neurological deficits such as hemiparesis, sensory changes, or difficulty with speech and language.
In cases in which lesions occlude or obstruct the cerebrospinal fluid pathways, the patients may present with progressive signs of increased intracranial pressure.
DIAGNOSTIC PROCEDURES FOR LOW-GRADE GLIOMAS
A summary of diagnostic procedures is provided in Table 2 . In patients presenting with seizure disorders, EEG can be used to diagnose the disease. The characteristic EEG appearance of a low-grade glioma includes slow or delta waves as well as any associated epileptiform activity. Currently the most commonly used diagnostic modality is the imaging study, usually MR imaging, which provides exquisite detail both of the anatomy of the lesion and often of its pathophysiology (Tables 3 and 4) . A stereotactic biopsy sampling procedure is commonly performed in attempts to diagnose presumed low-grade gliomas detected by imaging studies. These biopsy procedures are usually effective; however, because the pathological findings are occasionally equivocal, one must always be concerned with a sampling error in tumors that contain areas of differing degrees of malignancy.
TREATMENT OF LOW-GRADE GLIOMAS
In a significant proportion of detected low-grade gliomas the patients may be appropriate candidates for conservative management. Patients harboring these lesions can be treated with anticonvulsant medication and repeated neurodiagnostic imaging studies, withholding intervention until there has been a change either clinically or radiologically. Partial resection may be appropriate for some low-grade astrocytomas, particularly those that are near important areas of the brain. Partial resection can result in long-term favorable results in patients with pilocytic astrocytomas, dysembryoplastic neuroepithelial tumors, and some gangliogliomas and pleomorphic xanthoastrocytomas.
Radical or total resection is the surgical procedure of choice for all forms of glioma, because in many of the patients with these tumors complete removal of the lesion can result in cure. On occasion, cortical mapping or awake surgery may be helpful in allowing complete resection to be accomplished without producing unacceptable neurological deficits. The role of radiotherapy remains quite controversial in the management of most low-grade gliomas (Table 5 ). Although there is some evidence that low-grade ordinary astrocytomas may benefit from radiation therapy, radiotherapy has not been applied in a consistent fashion, and the dose-response relationship is not clear. Some investigators have used radiosurgery in an attempt to provide more focused delivery of radiation for low-grade gliomas, and in the future this may prove to have a role in combined management protocols.
Because these lesions do not have features of anaplasia, the role for chemotherapy is limited. In an attempt to avoid radiotherapy in very young patients, some chemotherapy programs have been advocated. In patients with clear signs of tumor progression despite prior therapy, chemotherapy may also be considered; nitrosourea agents seem to be the most logical choices at the present time. Occasionally other experimental therapies have been used in the management of low-grade glioma. These include interstitial brachytherapy, immunotherapy, photodynamic therapy, and hyperthermia.
PATHOGENIC FEATURES
At one time it was thought that the most common lowgrade gliomas, namely astrocytomas and oligodendrogliomas, arose from separate precursor cells. The results of more recent laboratory work seems to support the concept that there may be a single precursor cell that can differentiate into neuronal elements and into all types of glial elements as well.
It is clear that some astrocytomas are the result of genetic disturbances, particularly those associated with known genetically linked diseases. Tumorigenesis may be the result of oncogene activity, but more commonly it is the result of the loss of tumor suppressor genes. Both of these mechanisms are being investigated using the techniques of molecular biology and molecular neuropathology.
Like their more malignant counterparts, most low-grade gliomas tend toward invasiveness, and only occasionally are they truly well-circumscribed lesions. The inherently invasive nature of many of these tumors suggests that surgery alone may not be adequate to provide long-term control and that multimodality approaches may be ultimately more effective. It is true, however, that some forms of low-grade gliomas are basically indolent hamartomatous lesions that have very little growth potential and very little ability for malignant transformation. It is evident that accurate histopathological diagnosis is critical in determining both prognosis and recommendations for therapy (Table 6) .
Although many of these lesions are considered benign, the authors of natural history studies have tended to show that they actually behave in a rather aggressive fashion, and the prognosis for many of them is guarded. In cases of ordinary astrocytomas the 5-year survival rate is approximately 50%, and the tendency toward malignant progression over time is clear. Table 7 summarizes the results of a number of retrospective studies designed to estimate the frequency of malignant degeneration in patients with astrocytoma who are followed over time.
HISTOLOGICAL FEATURES OF LOW-GRADE GLIOMAS
Examples of the key features of the histopathology of low-grade gliomas are given in Figs. A-M. Click to view: pilocytic astrocytoma (Figs. A1-A10) , diffuse low-grade astrocytoma (Figs. B1-B20 ), pleomorphic xanthoastrocytoma, subependymal giant cell astrocytoma, and oligodendroglioma (Figs. C1-E9 ), mixed oligoastrocytoma, ependymoma, myxopapillary ependymoma, and choroid plexus papilloma (Figs. F1-I2) , ganglioglioma, dysembryoplastic neuroepithelial tumor, gangliocytoma, central neurocytoma (Figs. J1-M4 ).
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CONCLUSIONS
Major research efforts are directed toward the biological behavior of these interesting lesions. The authors of some studies have suggested that metabolic imaging may help differentiate those tumors destined for long-term control from those that will undergo malignant transformation. Tumor receptor studies and tumor genetic studies may allow various forms of intervention in which novel agents and novel strategies are used. Gene therapy may play a role in the treatment of low-grade gliomas as well as in the more malignant tumors, because they both probably share many of the same genetic predispositions.
Management of these lesions remains a challenge and should be treated as scientifically based as possible. There is a continuing need for careful and continued follow-up studies. 
